Gene therapy for genetic haematological disorders and immunodeficiencies

Journal of Internal Medicine

Volumn 249, Issue 4, 2001, Pages 379-390

  Kohn, D B ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Gene therapy; Haematopoietic stem cells; Haemoglobinopathies; Immune deficiency syndromes; Lysosomal storage diseases; Retroviral vectors

Indexed keywords

ADENOSINE DEAMINASE; CD34 ANTIGEN; GLUCOSYLCERAMIDASE; GRANULOCYTE COLONY STIMULATING FACTOR; LENTIVIRUS VECTOR; PROTEIN P47; RETROVIRUS VECTOR;

ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; BETA THALASSEMIA; BONE MARROW TRANSPLANTATION; CELL CYCLE; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; CONFERENCE PAPER; DNA MODIFICATION; ENZYME DEFICIENCY; ERYTHROCYTE DISORDER; ERYTHROPOIETIC PROTOPORPHYRIA; FANCONI ANEMIA; GAUCHER DISEASE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; GENETIC TRANSDUCTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINOPATHY; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IN VIVO STUDY; LEUKOCYTE DISORDER; LYSOSOME STORAGE DISEASE; MICROINJECTION; NONHUMAN; PRIORITY JOURNAL; X CHROMOSOMAL INHERITANCE;

ADENOSINE DEAMINASE; ANIMALS; FANCONI ANEMIA; GAUCHER DISEASE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEMATOLOGIC DISEASES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LENTIVIRUS; RETROVIRIDAE; SEVERE COMBINED IMMUNODEFICIENCY; TRANSDUCTION, GENETIC;

EID: 0035731827     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2001.00803.x     Document Type: Conference Paper

References (69)

1. Combination of interleukins 3 and 6 preserves stem cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells
2. Gene transfer to hematopoietic stem cells: Implications for gene therapy of human disease
3. Clinical trials of gene therapy using hematopoietic stem cells
4. Flt3 ligand induces proliferation of quiescent human bone marrow CD34+ CD38 cells and maintains progenitor cells in vitro
5. Thrombopoietin supports proliferation of human primitive hematopoietic cells in synergy with steel factor and/or interleukin-3
6. Engraftment and retroviral marking of CD34+ and CD34+/CD38 human hematopoietic progenitors assessed in immunedeficient mice
7. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells
8. Adhesion to fibronectin maintains regenerative capacity during ex vivo culture and transduction of human hematopoietic stem cells
9. Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor
10. Prolonged high-level detection of retrovirally marked hematopoietic cells in nonhuman primates using clinically feasible methods
11. kip-1 coupled with transforming growth factor neutralization induces cell-cycle entry and increases retroviral transduction of primitive human hematopoietic cells
12. Release from quiescence of CD34+ CD38- human umbilical cord blood cells reveals their potentiality to engraft adults
13. Efficient transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors
14. Human immunodeficiency virus Type 1 vectors efficiently transduce human hematopoietic stem cells
15. Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1 based lentiviral vectors
16. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
17. HIV-1 genome nuclear import is mediated by a central DNA flap
18. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity
19. Analysis of the relative level of gene expression from different retroviral vectors used for gene therapy
20. Development of improved adenosine deaminase retroviral vectors
21. Retroviral mediated transfer of the human glucocerebrosidase gene into cultured Gaucher bone marrow
22. Retroviral-mediated transfer of the human α-L-iduronidase cDNA into human hematopoietic progenitor cells leads to correction in trans of Hurler fibroblasts
23. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation
24. Transcriptional silencing of retroviral vectors
25. Inactivation of a GFP retrovirus occurs at multiple levels in long-term repopulating stem cells and their differentiated progeny
26. Embryonic stem cell virus, a recombinant murine retrovirus with expression in embryonal stem cells
27. Versatile retroviral vectors for potential use in gene therapy
28. Improved expression in murine hematopoietic and lymphoid cells after transplantation of bone marrow transduced with a modified retroviral vector
29. Genetic treatment of severe hemoglobinopathies: The combat against transgene variegation and transgene silencing
30. Scaffold attachment region-mediated enhancement of retro-viral expression in primary T cells
31. A chromatin insulator protects retrovirus vectors from chromosomal position effects
32. Glass needle-mediated microinjection of macromolecules and transgenes into primary human blood stem/progenitor cells
33. Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide
34. Restoration of lymphoid populations in a murine model of X-linked severe combined immunodeficiency by a gene-therapy approach
35. Restoration of lymphocyte function in Janus kinase-3 deficient mice by retroviral-mediated gene transfer
36. Preselection of retrovirally transduced bone marrow avoids subsequent stem cell gene silencing and age-dependent extinction of expression of human beta-globin in engrafted mice
37. Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer
38. Enhanced host defense after gene transfer in the murine p47phox-deficient model of chronic granulomatous disease
39. Long-term correction of phagocyte NADPH oxidase activity by retroviral-mediated gene transfer in murine X-linked chronic granulomatous disease
40. Phenotypic correction of Fanconi anemia group C knock-out mice
41. Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy
42. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients
43. Gene therapy for adenosine deaminase (ADA) deficiency
44. T lymphocyte-directed gene therapy for ADA-SCID. Initial trial results after 4 years
45. Bone marrow gene transfer in three patients with adenosine deaminase deficiency
46. Engraftment of gene-modified cells from umbilical cord blood in neonates with adenosine deaminase deficiency
47. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates
48. Human severe combined immunodeficiency: Genetic, phenotypic, and functional diversity in one hundred eight infants
49. Cloning of the gamma chain of the human IL-2 receptor
50. Gammac gene transfer in the presence of stem cell factor, flt-3L, interleukin-7 (IL-7), IL-1, and IL-15 cytokines restores T-cell differentiation from gammac(-) X-linked severe combined immunodeficiency hematopoietic progenitor cells in murine fetal thymic organ culture
51. Retroviral-mediated gene correction for X-linked severe combined immunodeficiency
52. Correction of interleukin-2 receptor function in X-SCID lymphoblastoid cells by retrovirally mediated transfer of the γc gene
53. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
54. Genetic, biochemical, and clinical features of chronic granulomatous disease
55. Genetic correction of p67phox deficient chronic granulomatous disease using peripheral blood progenitor cells as a target for retrovirus mediated gene transfer
56. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease
57. Gaucher disease
58. Bone marrow transplantation in Gaucher disease
59. Long-term follow-up of the first successful bone marrow transplantation in Gaucher disease
60. Retroviral transfer of the glucocerebrosidase gene into CD34+ cellls from patients with Gaucher disease: In vivo detection of transduced cells without myeloablation
61. Retrovirus-mediated transfer of the cDNA for human glucocerebrosidase into peripheral blood repopulating cells of patients with Gaucher's disease
62. Molecular biology of Fanconi anemia: Implications for diagnosis and therapy
63. Allogeneic bone marrow transplantation in Fanconi anemia
64. Functional correction of Fanconi anemia group A hematopoietic cells by retroviral gene transfer
65. In vivo selection of wild-type hematopoietic stem cells in a murine model of Fanconi anemia
66. Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC)
67. Mutagenesis of retroviral vectors transducing human β-globin gene and β-globin locus control region derivatives results in stable transmission of an active transcriptional structure
68. Generation of a high-titer retroviral vector capable of expressing high levels of the human beta-globin gene
69. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin